A physiologic role for testosterone in limiting estrogenic stimulation of the breast

Menopause

Volumn 10, Issue 4, 2003, Pages 292-298

  Dimitrakakis, Constantine ^a   Zhou, Jian ^a   Wang, Jie ^a   Belanger, Alain ^b,c   LaBrie, Fernand ^b,c   Cheng, Clara ^a   Powell, Douglas ^d   Bondy, Carolyn ^a,d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NONE

Author keywords

Androgen; Breast cancer; Estrogen; Estrogen receptor; Proliferation

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN; FLUTAMIDE; PROGESTERONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HORMONAL REGULATION; MAMMARY GLAND FUNCTION; MENOPAUSE; NONHUMAN; OVARIECTOMY; OVARY; OVARY FUNCTION; OVARY INSUFFICIENCY; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 0038786584     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000055522.67459.89     Document Type: Article

References (39)

1. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001;56(6):361-376.
2. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283(4):485-491.
3. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92(4):328-332.
4. Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997; 18(7):557-562.
5. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993;170(1):37-43.
6. Labrie F, Simard J, de Launoit Y, et al. Androgens and breast cancer. Cancer Detect Prev 1992;16(1):31-38.
7. Grino PB, Griffin JE, Cushard WG Jr, Wilson JD. A mutation of the androgen receptor associated with partial androgen resistance, familial gynecomastia, and fertility. J Clin Endocrinol Metab 1988; 66(4):754-761.
8. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 1997;50(6):929-933.
9. Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2(2):132-134.
10. Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet 1993;5(2):109-110.
11. Rebbeck TR, Kantoff PW, Krithivas K, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am JHum Genet 1999;64(5):1371-1377.
12. Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002;62(4):1045-1049.
13. Giguere Y, Dewailly E, Brisson J, et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001;61(15):5869-5874.
14. Menin C, Banna GL, De Salvo G, et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001;168(1):31-36.
15. Zhou J, Anderson K, Bievre M, Ng S, Bondy CA. Primate mammary gland insulin-like growth factor system: cellular localization and regulation by sex steroids. J Investig Med 2001;49(1):47-55.
16. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14(12):1725-1730.
17. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000;7(2):211-247.
18. Miller TL, Huzel NJ, Davie JR, Murphy LC. C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol 1993;91:83-89.
19. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998;18(8):4499-4508.
20. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21(3):427-433.
21. Davis S. Androgen replacement in women: a commentary. J Clin Endocrinol Metab 1999;84(6):1886-1891.
22. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343(10):682-688.
23. Jayo MJ, Register TC, Hughes CL, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig 2000;7(4):257-265.
24. Hall RE, Aspinall JO, Horsfall DJ, et al. Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer 1996;74(8):1175-1180.
25. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170(1):31-35.
26. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52(5):459-467.
27. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Annu Rev Physiol 2001;63:165-192.
28. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER β inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142(9):4120-4130.
29. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quantification of estrogen receptor alpha and β expression in sporadic breast cancer. Oncogene 2001;20(56):8109-8115.
30. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61(6):2537-2541.
31. Jensen EV, Cheng G, Palmieri C, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 2001;98(26):15197-15202.
32. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000;156(1):29-35.
33. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor β expression in breast cancer. Cancer Lett 2001;163(2):207-212.
34. Gustafsson JA, Warner M. Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 2000;74(5):245-248.
35. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7(2):235-239.
36. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83(12):1688-1695.
37. Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 2001;22(9):1521-1526.
38. Park JJ, Irvine RA, Buchanan G, et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000;60(21):5946-5949.
39. Yeh S, Hu YC, Rahman M, et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCAI in prostate cancer cells. Proc Natl Acad Sci U S A 2000;97(21):11256-11261.